| Revista: | Annals of hepatology |
| Base de datos: | PERIÓDICA |
| Número de sistema: | 000416128 |
| ISSN: | 1665-2681 |
| Autores: | Widholzer Galant, Larissa1 Mattos, Angelo Alves de1 Menti, Eduardo2 Valiatti, Fabiana Borba2 Mattos, Angelo Zambam de1 Porawski, Marilene2 Hartmann, Antonio2 Rhoden, Claudia Ramos2 |
| Instituciones: | 1Irmandade Santa Casa de Misericordia de Porto Alegre, Servico de Gastroenterologia, Porto Alegre, Rio Grande do Sul. Brasil 2Universidade Federal de Ciencias da Saude de Porto Alegre, Porto Alegre, Rio Grande do Sul. Brasil |
| Año: | 2013 |
| Volumen: | 12 |
| Número: | 3 |
| Paginación: | 425-433 |
| País: | México |
| Idioma: | Inglés |
| Tipo de documento: | Artículo |
| Enfoque: | Experimental, analítico |
| Resumen en inglés | Hepatocellular carcinoma is one of the most commonly diagnosed malignant tumors in the world, and it typically has a poor prognosis. Extensive studies have examined the effects of non-steroidal anti-inflammatory drugs selective to COX-2 on the chemoprevention of various tumors. The objective of this study is to observe the effect of celecoxib on the development of liver tumors in rats. Material and methods. Hepatocellular carcinoma was induced in a group of 75 rats with the carcinogen diethylnitrosamine. The animals were divided into 5 groups. Three groups received various doses of celecoxib, one group received indomethacin, and a control group received no non-steroidal selective anti-inflammatory drugs. Results. The experimental model was considered to be successful because 78% of the rats in the control group developed liver tumors. The number of neoplastic lesions was similar among the celecoxib, indomethacin and control groups, although the nodule diameter of the lesions was smaller in the celecoxib group. Better results were observed in animals that received celecoxib at doses of 6 and 9 mg/kg/ day; 4 rats in these groups did not show any neoplastic histological lesions, and a greater proportion of the nodules in the other animals in these groups were benign than in the groups that did not use celecoxib. Conclusions. These results suggest that celecoxib may play a role in modifying the natural history of hepatocellular carcinoma development |
| Disciplinas: | Medicina |
| Palabras clave: | Gastroenterología, Oncología, Medicina experimental, Carcinoma hepatocelular, Histología, Estrés oxidativo, Inhibición de COX-2, Indometacina, Celecoxib |
| Keyword: | Gastroenterology, Oncology, Experimental medicine, Hepatocellular carcinoma, Histology, Oxidative stress, COX-2 inhibition, Indomethacin, Celecoxib |
| Texto completo: | Texto completo (Ver PDF) |
